It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JAGX’s FA Score shows that 1 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JAGX’s TA Score shows that 6 TA indicator(s) are bullish while SRPT’s TA Score has 5 bullish TA indicator(s).
JAGX (@Biotechnology) experienced а +7.62% price change this week, while SRPT (@Biotechnology) price change was +6.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was -13.21%, and the average quarterly price growth was -24.46%.
JAGX is expected to report earnings on May 19, 2023.
SRPT is expected to report earnings on Jul 30, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
JAGX | SRPT | JAGX / SRPT | |
Capitalization | 3.62M | 5.22B | 0% |
EBITDA | -29.1M | 317M | -9% |
Gain YTD | -78.178 | -55.761 | 140% |
P/E Ratio | 0.01 | 22.99 | 0% |
Revenue | 10.5M | 1.9B | 1% |
Total Cash | 13.3M | 1.36B | 1% |
Total Debt | 34.3M | 1.34B | 3% |
JAGX | SRPT | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 46 | |
PRICE GROWTH RATING 1..100 | 98 | 96 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 95 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JAGX's Valuation (14) in the Pharmaceuticals Generic industry is somewhat better than the same rating for SRPT (67) in the Biotechnology industry. This means that JAGX’s stock grew somewhat faster than SRPT’s over the last 12 months.
JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as SRPT (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to SRPT’s over the last 12 months.
SRPT's SMR Rating (46) in the Biotechnology industry is somewhat better than the same rating for JAGX (99) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew somewhat faster than JAGX’s over the last 12 months.
SRPT's Price Growth Rating (96) in the Biotechnology industry is in the same range as JAGX (98) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to JAGX’s over the last 12 months.
SRPT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to JAGX’s over the last 12 months.
JAGX | SRPT | |
---|---|---|
RSI ODDS (%) | 1 day ago82% | 1 day ago74% |
Stochastic ODDS (%) | 1 day ago79% | 1 day ago77% |
Momentum ODDS (%) | 1 day ago79% | 1 day ago81% |
MACD ODDS (%) | 1 day ago78% | 1 day ago64% |
TrendWeek ODDS (%) | 1 day ago80% | 1 day ago73% |
TrendMonth ODDS (%) | 1 day ago90% | 1 day ago75% |
Advances ODDS (%) | 7 days ago83% | 4 days ago74% |
Declines ODDS (%) | 3 days ago90% | 1 day ago77% |
BollingerBands ODDS (%) | 1 day ago79% | 1 day ago79% |
Aroon ODDS (%) | 1 day ago90% | 1 day ago69% |
A.I.dvisor tells us that JAGX and HEPA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and HEPA's prices will move in lockstep.
Ticker / NAME | Correlation To JAGX | 1D Price Change % | ||
---|---|---|---|---|
JAGX | 100% | -1.81% | ||
HEPA - JAGX | 29% Poorly correlated | -6.09% | ||
DVHGF - JAGX | 27% Poorly correlated | N/A | ||
AFMD - JAGX | 26% Poorly correlated | +1.03% | ||
SNPX - JAGX | 26% Poorly correlated | -5.37% | ||
SLNO - JAGX | 26% Poorly correlated | +0.07% | ||
More |